Glycerol restores p53-dependent radiosensitivity of human head and neck cancer cells bearing mutant p53

被引:0
|
作者
K Ohnishi
I Ota
A Takahashi
T Ohnishi
机构
[1] Department of Biology,Department of Otorhinolaryngology
[2] Nara Medical University,undefined
来源
British Journal of Cancer | 2000年 / 83卷
关键词
p53; apoptosis; Bax; radiosensitivity; glycerol; chemical chaperone;
D O I
暂无
中图分类号
学科分类号
摘要
Mutation or inactivation of p53 is known to be present in approximately 50% of human cancers. We propose here a novel strategy for overcoming this problem in mutant p53-targeting cancer therapies. We examined the restoration of radiation-induced p53-dependent apoptosis by a chemical chaperone (glycerol) in human head and neck cancer cells (SAS cells, showing wild-type p53 phenotype). SAS cells transfected with mutant p53 (SAS/m p53) showed radioresistance compared with SAS cells (SAS/ neo) transfected with neo vector as a control, but became radiosensitive when pre-treated with glycerol before X-ray irradiation. Apoptosis in the SAS/m p53 cells was induced by X-rays with glycerol pre-treatment, but not without glycerol pre-treatment, whereas apoptosis in the SAS/ neo cells was induced in both cases. Gel mobility-shift assays showed that after X-ray irradiation combined with glycerol pre-treatment, mp53 was able to bind to the sequence-specific region upstream of the bax gene regulating apoptosis. These results suggest that glycerol is effective in inducing a conformational change of p53 and restoring normal function to mp53, leading to enhanced radiosensitivity through the induction of apoptosis. This novel tool for enhancement of radiosensitivity in cancer cells bearing mp53 may be useful for p53-targeted radiotherapy. © 2000 Cancer Research Campaign http://www.bjcancer.com
引用
收藏
页码:1735 / 1739
页数:4
相关论文
共 50 条
  • [31] Multidisciplinary treatment with P53 biomarker for head and neck cancer
    Fukazawa, H
    Takagi, R
    Ohashi, Y
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 521 - 525
  • [32] Mutant p53 in colon cancer
    Nakayama, Mizuho
    Oshima, Masanobu
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 267 - 276
  • [33] p53 status and radiosensitivity
    Bodis, S
    Pruschy, M
    Glanzmann, C
    Krek, W
    Lowe, SW
    Fisher, DE
    PROGRESS IN RADIO-ONCOLOGY VI, 1998, : 481 - 489
  • [34] The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer
    Götte, K
    Riedel, F
    Neubauer, J
    Schäfer, C
    Coy, JF
    Hörmann, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (02) : 331 - 336
  • [35] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    A Vinyals
    M A Peinado
    M Gonzalez-Garrigues
    M Monzó
    R D Bonfil
    A Fabra
    Gene Therapy, 1999, 6 : 22 - 33
  • [36] Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner
    Wamsley, J. J.
    Gary, C.
    Biktasova, A.
    Hajek, M.
    Bellinger, G.
    Virk, R.
    Issaeva, N.
    Yarbrough, W. G.
    ONCOGENESIS, 2017, 6 : e314 - e314
  • [37] Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner
    J J Wamsley
    C Gary
    A Biktasova
    M Hajek
    G Bellinger
    R Virk
    N Issaeva
    W G Yarbrough
    Oncogenesis, 2017, 6 : e314 - e314
  • [38] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    Vinyals, A
    Peinado, MA
    Gonzalez-Garrigues, M
    Monzó, M
    Bonfil, RD
    Fabra, A
    GENE THERAPY, 1999, 6 (01) : 22 - 33
  • [39] Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
    Watanabe, T
    Sullenger, BA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) : 8490 - 8494
  • [40] Head and neck cancers and P53 immunogenicity
    Bensadoun, RJ
    Fontana, X
    Pivot, X
    Dassonville, O
    Poissonnet, G
    Vallicioni, J
    Milano, G
    Demard, F
    Schneider, M
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 1137 - 1140